<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755764</url>
  </required_header>
  <id_info>
    <org_study_id>1681431</org_study_id>
    <nct_id>NCT04755764</nct_id>
  </id_info>
  <brief_title>Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy</brief_title>
  <official_title>The Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by Impedance Cardiography in Early Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marshall University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marshall University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to characterize the effect of labetalol, atenolol, and&#xD;
      nifedipine on maternal hemodynamics early in pregnancy. Patients will be given medication&#xD;
      based on their hemodynamics and asked to return for a repeat measurement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When a patient presents to the Maternal Hypertension Center at Cabell Huntington Hospital,&#xD;
      she will receive a non-invasive hemodynamic assessment via the NICaS system as per usual&#xD;
      protocol. The NICaS system uses impedance cardiography which provides a reliable assessment&#xD;
      of cardiovascular, respiratory, and fluid parameters. In typical practice, the vasodilator&#xD;
      nifedipine is initiated for increased systemic vascular resistance and elevated cardiac&#xD;
      output is treated with beta blockade (via either atenolol or labetalol). The medication to be&#xD;
      given to each subject will be based on their hemodynamics. Specifically, nifedipine will be&#xD;
      given for a mean arterial pressure &gt;100 and a beta blocker will be given for a cardiac output&#xD;
      &gt;8 l/min. The patients will be asked to return in one week for repeat ICG measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.</time_frame>
    <description>Measured in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.</time_frame>
    <description>Measured in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.</time_frame>
    <description>Measured in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.</time_frame>
    <description>Measured in beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.</time_frame>
    <description>Measured in liters per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic vascular resistance</measure>
    <time_frame>Initial assessment of hemodynamic parameters will be measured. A change from baseline will be assessed one week later.</time_frame>
    <description>Measured by dynes Â· sec/cm^-5</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Systolic Hypertension</condition>
  <condition>Pregnancy Related</condition>
  <condition>Diastolic Hypertension</condition>
  <condition>Cardiac Output, Low</condition>
  <condition>Cardiac Output, High</condition>
  <arm_group>
    <arm_group_label>Beta blockade</arm_group_label>
    <description>Beta blocker (labetalol or atenolol) will be given for a cardiac output &gt;8 l/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <description>Nifedipine will be given for a mean arterial pressure &gt;100.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <description>Beta blocker</description>
    <arm_group_label>Beta blockade</arm_group_label>
    <other_name>Normodyne</other_name>
    <other_name>Trandate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Beta blocker</description>
    <arm_group_label>Beta blockade</arm_group_label>
    <other_name>Tenormin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Calcium channel blocker</description>
    <arm_group_label>Nifedipine</arm_group_label>
    <other_name>Adalat CC</other_name>
    <other_name>Afeditab CR</other_name>
    <other_name>Nifediac CC</other_name>
    <other_name>Nifedical XL</other_name>
    <other_name>Procardia</other_name>
    <other_name>Procardia XL</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the Maternal Hypertension Center at Cabell Huntington Hospital.&#xD;
        Consent will be obtained prior to enrollment. Patient age range will be from age 18 to&#xD;
        approximately 45.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting to Maternal Hypertension Center at Cabell Huntington Hospital&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  18-45 years old.&#xD;
&#xD;
          -  Willing to provide informed consent&#xD;
&#xD;
          -  Gestational age prior to 15 weeks gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking patients, patients&#xD;
&#xD;
          -  &lt;18 years old or &gt;45 years old&#xD;
&#xD;
          -  Not willing or able to provide consent&#xD;
&#xD;
          -  Gestational age &gt;15 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesse Cottrell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marshall University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morgan Ruley, MS</last_name>
    <phone>(304) 691-1458</phone>
    <email>kelley115@marshall.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesse Cottrell, MD</last_name>
    <phone>(304) 691-1400</phone>
    <email>cottrellje@marshall.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternal Hypertension Center at Cabell Huntington Hospital</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Cottrell, MD</last_name>
      <phone>304-691-1400</phone>
      <email>cottrellje@marshall.edu</email>
    </contact>
    <contact_backup>
      <last_name>Morgan Ruley, MS</last_name>
      <phone>3046911458</phone>
      <email>kelley115@marshall.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jesse Cottrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Chaffin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marshall University</investigator_affiliation>
    <investigator_full_name>Jesse Cottrell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiac Output, Low</mesh_term>
    <mesh_term>Cardiac Output, High</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

